Demand for AppsVillage products and services increases

Published 02-APR-2020 10:35 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

AppsVillage Australia Ltd (ASX: APV), a SaaS solutions provider for small and medium businesses (SMBs), has provided a promising financial and operational update following a strong March quarter.

During this period, the company delivered higher than expected revenue results, exceeding previous guidance provided just over a month ago.

AppsVillage delivered monthly recurring revenues of more than $150,000 and annualised recurring revenues of approximately $1.8 million, representing an increase of about 250% compared with the previous corresponding quarter, and a 36% increase on the December quarter.

AppsVillage provides an easy and inexpensive SAAS solution that allows small-to-medium businesses to create and manage their own mobile application as a means of connecting with their customers and growing their business.

AppsVillage’s technology has automated the design, development, maintenance and marketing of mobile apps, allowing any business to build, preview and launch their own application without the need for code writing or digital marketing knowledge.

The robust performance in the March quarter represents a continuation of consistent growth in monthly and annual recurring revenue as can be seen below.

Targeting higher margin areas

AppsVillage also delivered 7,840 paying SMBs during the quarter, an increase of more than 250% compared to the first quarter of 2019 and a 22% increase on the December quarter.

These record results were delivered following the implementation of an aggressive and targeted strategy to scale and acquire new customers in high margin geographies such as the US, Australia and the UK.

These results have been delivered despite the outbreak of COVID-19, demonstrating the company’s ability to deliver strong and continuous organic customer and revenue growth in the current uncertain environment.

Management remains confident in its ability to continue to deliver financial and operational growth throughout this year and as a result has projected annual recurring revenues of $4.0 million by the end of 2020.

Underlining the increasing demand for the group’s products in light of the coronavirus, founder and chief executive Max Bluvband said, ”The COVID-19 outbreak is having an unprecedented impact globally.

‘’These are challenging times for all humanity and particularly for small businesses.

‘’Our platform is proving to be essential to SMBs continuous operation and sustainability and our financial results reflect that.”



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X